Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism

Neuropsychopharmacology

Volumn 27, Issue 1, 2002, Pages 105-119

  Lerer, Bernard ^a   Segman, Ronnen H ^a   Fangerau, Heiner ^b   Daly, Ann K ^c   Basile, Vincenzo S ^d   Cavallaro, Roberto ^e   Aschauer, Harald N ^f   McCreadie, Robin G ^g   Ohlraun, Stephanie ^b   Ferrier, Nicol ^c   Masellis, Mario ^d   Verga, Massimiliano ^e   Scharfetter, Joachim ^f   Rietschel, Marcella ^b   Lovlie, Roger ^h   Levy, Uriel Heresco ⁱ   Meltzer, Herbert Y ^j   Kennedy, James L ^d   Steen, Vidar M ^h   Macciardi, Fabio ^d  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF BONN   (Germany)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF TORONTO   (Canada)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g Crichton Royal Hospital   (United Kingdom)

^h HAUKELAND UNIVERSITY HOSPITAL   (Norway)

ⁱ HERZOG HOSPITAL   (Israel)

^j Psychiatric Hospital at Vanderbilt   (United States)

more..

Author keywords

Antipsychotic drugs; Dopamine D3 receptors; Molecular genetics; Pharmacogenetics; Pharmacogenomics; Schizophrenia; Single nucleotide polymorphism; Tardive dyskinesia

Indexed keywords

DOPAMINE 3 RECEPTOR; GLYCINE; SERINE;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; INVOLUNTARY MOVEMENT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE; TARDIVE DYSKINESIA;

ADULT; AGED; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; DYSKINESIA, DRUG-INDUCED; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLYCINE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SERINE;

EID: 0036283004     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00293-2     Document Type: Article

References (80)

1. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients
2. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype
3. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response
4. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia
5. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia
6. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia
7. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia
8. HLA and TD
9. Immunogenetic markers in chlorpromazine induced TD
10. Psychiatric genetics '99: The challenges of psychopharmacogenetics
11. Tardive dyskinesia outcomes: Clinical and pharmacological correlates of remission and persistence
12. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia
13. Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese
14. Pharmacogenetics of schizophrenia
15. Statistical modeling of interlocus interactions in a complex disease: Rejection of the multiplicative model of epistasis in type I diabetes
16. Complex promoter and coding region b2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness
17. Treatment of schizophrenia in low-income countries
18. The correlation between relatives on the supposition of Mendelian inheritance
19. Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients
20. Manganese superoxide dismutase dene polymorphism and schizophrenia: Relation to tardive dyskinesia
21. Search for a susceptibility locus to tardive dyskinesia
22. Risk of tardive dyskinesia in older patients
23. Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979
24. Tardive dyskinesia: Epidemiological and clinical presentation
25. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia
26. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: Causes and consequences
27. 3 receptor as a useful polymorphism for investigating psychiatric disorders
28. Cumulative meta-analysis of therapeutic trials for myocardial infarction
29. 3 receptor gene
30. Pharmacogenetics of antidepressant and mood stabilising drugs: A review of candidate gene studies and future research directions
31. Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder
32. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients
33. Homozygosity for Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients
34. Proposed schizophrenia related gene polymorphism: Expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki forest virus system
35. A genetic study of tardive dyskinesia in an Italian population of chronic schizophrenics
36. Dopamine receptor genes and tardive dyskinesia
37. Pharmacogenetics of antipsychotic treatment: Lessons learned from Clozapine
38. HLA antigens in TD
39. Genetic association analysis between CyP2D6*2 allele and tardive dyskinesia in schizophrenic patients
40. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics
41. The language of gene interaction
42. Pharmacogenomics of psychiatric disorders
43. Pharmacogenetics and psychopharmacotherapy
44. Use of unlinked genetic markers to detect population stratification in association studies
45. Dopamine D3 receptor variant and tardive dyskinesia
46. Searching for genetic determinants in the new millennium
47. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer Am
48. Possible genetic factors underlying the pathophysiology of tardive dyskinesia
49. Pharmacogenetics and the practice of medicine
50. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients
51. Association of tardive dyskinesia and dopamine D3 and D4 receptor gene polymorphism
52. Research diagnoses for tardive dyskinesia
53. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia
54. Genotypic association between the dopamine D3 receptor gene and tardive dyskinesia in chronic schizophrenia
55. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility
56. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia
57. Interactive effect of cytochrome P450 17a-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia
58. Genetic factors underlying drug induced tardive dyskinesia
59. Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia
60. A rating scale for tardive dyskinesia
61. Polymorphism within the serotonin transporter and antidepressant efficacy of fluvoxamine
62. Changes in prevalence, severity, and recovery in tardive dyskinesia with age
63. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics
64. Dopamine D3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
65. Pharmacogenetics: A new diagnostic tool in the management of antidepressive drug therapy
66. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: A study in three rat strains
67. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism inthe serotonin type 2A receptor
68. Pharmacogenetics and the serotonin system: Initial studies and future directions
69. The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree
70. Familial occurrence of tardive dyskinesia
71. How many diseases does it take to map a gene with SNPs?
72. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors
73. Familial tardive dyskinesia
74. Gender differences in tardive dyskinesia: A critical review of the literature
75. Familial psychosis and vulnerability to tardive dyskinesia
76. On the significance of subterritories in the "accumbens" part of the rat ventral striatum